JAMA oncology 2025 Apr 03
Management of EGFR-Variant and ALK-Positive Non-Small Cell Lung Cancer Brain Metastasis.   

Related Questions

Can SRS or whole brain radiotherapy be reserved for progression in these young, healthy patients?